Fig. 1: Efficacy and multi-omic analysis workflow in MIST4.

A Upper panel. Spider plot showing the change in tumour size (% assessed by modified RECIST) against time (weeks) within 24 weeks. Dashed lines show threshold corresponding to partial response (−30% lower band) or disease progression (+20% upper band). Lower panel. Swimmer plot showing the duration of treatment measured within 24 weeks. B 26 patients with either pleural or peritoneal mesothelioma were recruited into MIST4 and received atezolizumab and bevacizumab (AtzBev), administered intravenously every 21 days until disease progression. Response to treatment was dichotomised into two groups; showing tumour reduction (blue) or growth (purple) as the best response, respectively. Diagnostic tumour blocks were subjected to whole exome and transcriptome sequencing. Spatial phenotyping by multiplex immunofluorescence was used to interrogate the immune landscape, and gut microbiota was 16S RNA sequenced. Features enriched in tumours showing either growth or reduction were inferred by ensemble machine learning (random forests, extreme gradient boosting).